Radmila Kanceva
Fresenius Kabi SwissBioSim GmbH · Swedish Orphan Biovitrum · Fresenius Kabi SwissBioSim
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Radmila Kanceva as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04018599 · Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSFresenius Kabi SwissBioSim GmbH · completed · Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis · study director
- Ph2/Ph3NCT03985423 · A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHSwedish Orphan Biovitrum · terminated · Hemophagocytic Lymphohistiocytoses · study director
- Ph1NCT03251339 · Safety and Immunogenicity of MSB11455 in Healthy ParticipantsFresenius Kabi SwissBioSim GmbH · completed · Healthy · study director
- Ph1NCT03251248 · Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy SubjectsFresenius Kabi SwissBioSim GmbH · completed · Healthy · study director
- Ph2/Ph3NCT01818492 · Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisSwedish Orphan Biovitrum · completed · Primary Haemophagocytic Lymphohistiocytosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:52 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.Am J Nephrol · 20178 citationsRCR 0.5
- Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double-blind trial.Pharmacol Res Perspect · 20205 citationsRCR 0.4
- 5 citationsRCR 0.4